QTTB vs FGL Comparison

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Founder Group Ltd acts as an end-to-end Engineering, Procurement, Construction, and Commissioning solutions provider for solar PV facilities in Malaysia. The segments of the company are large-scale solar projects and commercial and industrial (C&I) solar projects. Large-scale solar projects of the company are utility-scale solar PV power plants with installed generating capacity of 1 MWac or more, and C&I projects of the company are smaller-scale solar projects where the solar PV systems are installed on rooftops and are designed to generate electricity for commercial and industrial properties for their consumption at factories, warehouses, and commercial stores. The company derives its revenue from Malaysia.